Is Indefinite Dysplasia a Risk Factor for Advanced Colorectal Neoplasia in Patients with Inflammatory Bowel Disease?

Jae Jun Park

doi:10.4166/kjg.2019.74.4.242

Journal List > Korean J Gastroenterol > v.74(4) > 1135720

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Park: Is Indefinite Dysplasia a Risk Factor for Advanced Colorectal Neoplasia in Patients with Inflammatory Bowel Disease?

Research Update

The Korean Journal of Gastroenterology 2019; 74(4): 242-244.

Published online: 25 October 2019

DOI: https://doi.org/10.4166/kjg.2019.74.4.242

Is Indefinite Dysplasia a Risk Factor for Advanced Colorectal Neoplasia in Patients with Inflammatory Bowel Disease?

Jae Jun Park

Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Correspondence to: Jae Jun Park, Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1993, Fax: +82-2-393-6884, jaejpark@yuhs.ac

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138:746–774.

2. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015; 81:489–501.

3. American Society for Gastrointestinal Endoscopy Standards of Practice Committee. Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015; 81:1101–1121.

4. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010; 59:666–689.

5. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017; 11:3–25.

6. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14:931–968.

7. Löfberg R, Broström O, Karlén P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology. 1990; 99:1021–1031.

8. Broström O, Löfberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study. Gut. 1986; 27:1408–1413.

9. van Schaik FD, ten Kate FJ, Offerhaus GJ, et al. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis. 2011; 17:1108–1116.

10. Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010; 16:1352–1356.

11. Lai KK, Horvath B, Xie H, et al. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis. 2015; 21:378–384.

12. Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015; 110:1022–1034.

13. Wen KW, Rabinovitch PS, Wang D, Huang D, Mattis AN, Choi WT. Utility of DNA flow cytometric analysis of paraffin-embedded tissue in the risk stratification and management of 'indefinite for dysplasia' in patients with inflammatory bowel disease. J Crohns Colitis. 2019; 13:472–481.

14. Choi WT, Rabinovitch PS, Wang D, Westerhoff M. Outcome of “indefinite for dysplasia” in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer. Hum Pathol. 2015; 46:939–947.

15. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6:1225–1230.

16. Mahmoud R, Shah SC, Torres J, et al. Association between indefinite dysplasia and advanced neoplasia in patients with inflammatory bowel diseases undergoing surveillance. Clin Gastroenterol Hepatol. 2019; 08. 22. [Epub ahead of print].

TOOLS

ORCID iDs: Jae Jun Park
https://orcid.org/0000-0001-9974-1658
Similar articles